Comparing the current results to its competitors, Coherus Oncology Inc reported Revenue increase in the 2 quarter 2026 by 39.53 % year on year. The sales growth was above Coherus Oncology Inc 's competitors' average revenue growth of 9.44 %, achieved in the same quarter.
Coherus Oncology Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment with competition from larger pharmaceutical, generic pharmaceutical, specialty pharmaceutical, and biotechnology companies developing immuno-oncology and biosimilar products. Its product LOQTORZI competes in the U.S. market against several FDA-approved anti-PD-1 or PD-L1 antibody drugs, including Keytruda® (pembrolizumab) from Merck & Co., Inc., Opdivo® (nivolumab) from Bristol-Myers Squibb Company, Tecentriq® (atezolizumab) from Genentech, Inc., Imfinzi® (durvalumab) from AstraZeneca plc, Bavencio® (avelumab) from EMD Serono Inc. and Pfizer, Libtayo® (cemiplimab-rwlc) from Regeneron Pharmaceuticals, Inc., Jemperli (dostarlimab-gxly) from GlaxoSmithKline plc, and TEVIMBRA® (tislelizumab-jsgr) from BeiGene, Ltd. Competitors identified include AstraZeneca plc, BeiGene, Ltd., Bristol-Myers Squibb Company, EMD Serono Inc., Genentech, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Pfizer, and Regeneron Pharmaceuticals, Inc.
Strong sales growth of 39.53 % in Overall company contributed to Coherus Oncology inc increase in total revenue by 39.53 % Coherus Oncology inc improved its market share in this segment, to approximately 0.11 %.
January 18, 2024
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers SymposiumIn a recent press release, Coherus Biosciences announced that its investigational IL-27-targeted antibody, casdozokitug, has demonstrated promising early activity in combination with atezolizumab and bevacizumab in patients with gastrointestinal (GI) cancers. The results were presented at the 2024 ASCO GI Cancers Symposium, attracting significant attention from the medical community.During the Phase 2 clinical trial, casdozokitug was administered in combination with atezolizumab, an immune checkpoint inhibitor, and bevacizumab, an anti-angiogenic agent. The study aim...
Coherus Biosciences Inc., a leading biotechnology company, presented significant findings at the 2023 ESMO Immuno-Oncology Congress regarding the potential of their novel IL-27-targeted antibody, Casdozokitug. In combination with an anti-PD-1 antibody, this first-in-class therapy exhibited remarkable anti-tumor activity, with partial responses observed in two out of nine squamous non-small cell lung cancer (NSCLC) patients. This breakthrough development in lung cancer treatment has generated considerable excitement within the medical and scientific communities. Clinical Trial Results: The Phase 1/2 clinical trials of Casdozokitug have revealed encouraging data, underscoring its potential in...
Cerus Corporation's business model revolves around developing and commercializing innovative technologies and products for the enhancement of blood safety.
Biogen Incs business model focuses on researching, developing, and commercializing innovative therapies primarily for neurological and neurodegenerative diseases, emphasizing advancements in precision medicine and patient care.
Amneal Pharmaceuticals Inc operates as a fully integrated pharmaceutical company, primarily focused on the development, manufacturing, and distribution of generic and specialty pharmaceutical products. Their business model revolves around identifying market opportunities, conducting research to develop cost-effective formulations, and leveraging their expansive manufacturing capabilities to produce and distribute a wide range of pharmaceuticals to customers globally. Additionally, they aim to provide high-quality products at competitive prices while continuously investing in research and development to expand their product portfolio.
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Sources:
Coherus Oncology inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Coherus Oncology inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
